UNSPSC 51333513: Pridinol mesilate

This classification denotes an antipsychotic agent C20H25NO.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AQ4K0AJT6G, chemically known as 1,1-diphenyl-3-piperidinopropan-1-ol methanesulphonate, but more generally known as pridinol mesilate, which bears US NIH Compound Identifier 3041203. European Medicines Agency schedules Pridinol mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04036MIG.

Most nations, for tariff and trade purposes, schedule pridinol mesilate under HS 29333999 and SITC 51574. As of Q4 2014, PRIDINOL MESILATE remains US FDA's Preferred Term for this commodity. SMILES: CS(=O)(=O)O.C1CCC(CC1)C(CCN2CCCCC2)(C3CCCCC3)O.

UNSPSC 51333513 Pridinol mesilate is a Commodity code nominally designating a specific pharmaceutical active ingredient, but the recent state and local procurement activity tagged under it does not focus on pridinol itself. Instead, Seminole County, Florida has solicited through this code for naloxone and drug deactivation systems for community health initiatives, while the Texas Health and Human Services Commission and Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted broader pharmaceutical procurement vehicles. The code shows little relevant recent activity aligned with its stated product — state and local buyers are using it to source multi-source generic pharmaceuticals, over-the-counter products, and naloxone-based harm-reduction supplies rather than pridinol mesilate specifically. Issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing alliances serving multiple jurisdictions.

Recent activity is concentrated in Florida, Texas, and Minnesota. Seminole County posted an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Texas HHS Commission issued an RFI (HHS0017013, posted April 3, 2026) exploring vendor capacity for direct-to-manufacturer prescription fulfillment programs outside traditional pharmacy benefit manager and group purchasing organization channels. Minnesota's MMCAP administered an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon through three authorized wholesalers, with contract effectiveness July 1, 2026, and a two-year initial term. The code does not align cleanly with the pharmaceutical active-ingredient taxonomy it nominally represents; business development professionals should treat this as a miscoded or repurposed category and assess opportunity fit based on the broader pharmaceutical procurement vehicles actually in market.